Dermavant Sciences GmbH

Quick facts

Phase 2 pipeline

• Cerdulatinib 0.37% gel · Dermatology/Immunology
  Cerdulatinib is a dual JAK1/SYK inhibitor that suppresses inflammatory signaling pathways in immune cells to reduce skin inflammation.
• RVT-501 0.2% ointment
• RVT-501 0.5% ointment

Phase 1 pipeline

• RVT-501 0.5% topical ointment

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dermavant Sciences GmbH portfolio CI brief
• Dermavant Sciences GmbH pipeline updates RSS